Product Information
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.0778 per EA under NDC 33342013315. Its NADAC has been published 529 times since Aug 17, 2016.
FDA first approved this application on Feb 27, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB
Candesartan Cilexetil and HydrochlorothiazideStrength
32; 25 mg/1; mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342013315
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204100FDA Approved
2/27/2015
TE Code
AB
On Market Since
3/7/2015
Pharmacological Classes
Price Statistics
The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has been published 529 times since Aug 17, 2016, and over the history we have for it it has declined 69.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0778 per EA |
|---|---|
| All-time high | $4.1187 (Mar 13, 2019) |
| All-time low | $0.9491 (Oct 22, 2025) |
| 52-week high | $1.2433 |
| 52-week low | $0.9491 |
| Median price | $1.8517 |
| Average price | $2.1875 |
| Largest weekly change | +149.4% (Apr 21, 2021) |
| Weeks tracked | 529 |
| Tracking since | Aug 17, 2016 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Candesartan Cilexetil and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB, manufactured by Macleods Pharmaceuticals Limited, is $1.0778 per EA (NDC 33342013315), effective Sep 30, 2026.
How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB changed over time?
Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has declined 69.8%. It has been tracked across 529 weekly CMS publications since Aug 17, 2016.
What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
Since Aug 17, 2016, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has ranged from a low of $0.9491 (Oct 22, 2025) to a high of $4.1187 (Mar 13, 2019), with a median of $1.8517 per EA.
Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB (NDC 33342013315) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.